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Introduction: CD55, a glycosylphosphatidylinositol-anchored, complement-regulating protein (decay-accelerating
factor), is expressed by fibroblast-like synoviocytes (FLS) with high local abundance in the intimal lining layer.
We here explored the basis and consequences of this uncommon presence.
Methods: Synovial tissue, primary FLS cultures, and three-dimensional FLS micromasses were analyzed. CD55
expression was assessed by quantitative polymerase chain reaction (PCR), in situ hybridization, flow cytometry,
and immunohistochemistry. Reticular fibers were visualized by Gomori staining and colocalization of CD55 with
extracellular matrix (ECM) proteins by confocal microscopy. Membrane-bound CD55 was released from synovial
tissue with phospholipase C. Functional consequences of CD55 expression were studied in the K/BxN serum
transfer model of arthritis using mice that in addition to CD55 also lack FcγRIIB (CD32), increasing susceptibility for
immune complex-mediated pathology.
Results: Abundant CD55 expression seen in FLS of the intimal lining layer was associated with linearly oriented
reticular fibers and was resistant to phospholipase C treatment. Expression of CD55 colocalized with collagen type
I and III as well as with complement C3. A comparable distribution of CD55 was established in three-dimensional
micromasses after ≥3 weeks of culture together with the ECM. CD55 deficiency did not enhance K/BxN
serum-induced arthritis, but further exaggerated disease activity in Fcgr2b−/− mice.
Conclusions: CD55 is produced by FLS and deposited on the local collagen fiber meshwork, where it protects the
synovial tissue against immune complex-mediated arthritis.Introduction
Rheumatoid arthritis (RA) is a chronic, inflammatory
disease of primarily the peripheral joints. The develop-
ment of RA is characterized by transformation of the syn-
ovial tissue due to infiltration by reactive immune cells
and profound changes in the resident synovial cells giving
rise to inflammation, neovascularization, and hyperplasia,
and leading finally to cartilage destruction, bone erosion,
and functional impairment [1]. A unique cellular constitu-
ent of the synovial tissue is the fibroblast-like synoviocyte
(FLS), a cell of mesenchymal origin that is closely con-
nected to another synovial cell type of hematopoietic
origin, known as the intimal macrophage [2,3]. FLS and* Correspondence: j.hamann@amc.uva.nl
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stated.intimal macrophages constitute the intimal lining layer of
the joint. The healthy synovium comprises of two to three
cell layers, which can increase to up to fifteen layers in
RA. Subverting aberrant FLS proliferation, activation, and
functional transformation [3] is at the basis of the inten-
sive effort to treat the disease.
Recent studies using FLS placed into a preformed
matrix and cultured as a floating sphere established that
a large part of the behavior of these versatile cells is
dependent on their three-dimensional organization, but
independent of the presence of other mesenchymal or
bone marrow-derived cell lineages [4,5]. Indeed, FLS
micromasses develop a characteristic lining-sublining
organization, synthesize lubricin, critical to the lubricat-
ing ability of the synovial fluid, and organize a basement
membrane-like extracellular matrix (ECM), capable of
supporting monocyte survival and compaction into the
lining. When exposed to inflammatory stimuli, liningThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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the pathologic features of RA [5].
Our group and others previously described a highly
abundant expression of CD55 by FLS in the intimal lining
layer [6,7]. CD55 is a 70-kiloDalton (kDa) glycosylphospha-
tidylinositol (GPI)-anchored membrane protein possessing
four short consensus repeat domains [8]. It is traditionally
known to regulate activation of the immune system by fa-
cilitating the decay of the convertases that generate C3b
and C5b (decay-accelerating factors), thereby protecting
cells from the deleterious effects of complement activation
[8]. In line with this well-established function, mice lacking
CD55 are more susceptible to antibody-driven models of
inflammatory diseases [9]. Another function of CD55 is its
ability to bind the adhesion G protein-coupled receptor
(GPCR) CD97 [10]. Adhesion GPCRs mediate cell-cell and
cell-matrix interactions, and facilitate cell adhesion, orien-
tation, migration and positioning in various developmental
processes, in immunity, and in tumorigenesis [11]. We
previously demonstrated that CD97, expressed by immune
cells, binds CD55 in the intimal lining, implying a poten-
tial role in the infiltration of these cells [12]. Possibly re-
lated to the interaction of CD55 with CD97, we found
amelioration of collagen-induced arthritis and a trend to-
ward less severe K/BxN serum transfer arthritis in mice
that lack CD55 or CD97 [13].
Its abundance and functional diversity has focused
interest in the role of CD55 in synovial tissue. We re-
cently tested the ability of proinflammatory cytokines
and pathogen-associated molecular patterns to enhance
CD55 expression in cultured FLS and found only a rather
moderate upregulation by synthetic double-stranded ribo-
nucleic acids (RNAs) [14]. Applying in-depth analysis of
synovial tissue, three-dimensional FLS micromasses, and
the K/BxN serum-induced experimental model of arth-
ritis, we here explored the basis and the consequences of
the enhanced presence of CD55 in the intimal lining layer.
We demonstrate deposition of CD55 on a collagen fiber
network that compacts the FLS and describe a supportive
role of CD55 in protection from immune complex-
mediated K/BxN serum transfer arthritis.
Methods
Collection and processing of synovial tissue
Synovial tissue samples were obtained by needle arthros-
copy from patients with RA [15] who fulfilled the
American College of Rheumatology/European League
Against Rheumatism classification criteria [16]. The
Medical Ethics Committees of the Academic Medical
Center and Medical University of Vienna approved the
study, and all patients gave written informed consent.
Biopsy samples were snap-frozen in Tissue-Tek OCT
(Miles Inc, Elkhart, IN, USA) immediately after collection.
Cryostat sections (5 μm) were cut and stored at −80°C.Alternatively, synovial tissue obtained from synovectomy
or joint replacement surgery was fixed in 4% parafor-
maldehyde in phosphate-buffered saline (PBS), dehy-
drated, paraffin-embedded, sectioned at 4-μm thickness,
and stored at room temperature.
To remove GPI-linked proteins, thawed sections
were washed two times in PBS and treated with 1 U/ml
GPI-specific phospholipase C (Invitrogen, Bleiswijk,
Netherlands) for 45 min at 37°C. Then, sections were
fixed in acetone, washed with PBS, and stained as
described below.
Isolation, culture, and analysis of FLS
Single-cell suspensions were generated by finely mincing
freshly isolated synovial tissue samples, followed by
treatment with 0.5 mg/ml collagenase type VIII (Sigma-
Aldrich, Zwijndrecht, Netherlands) for 2 h at 37°C. The
obtained cell suspension was cultured in Dulbecco’s
modified Eagle medium (DMEM, 1 g/l D-glucose; Invi-
trogen), supplemented with 10% fetal calf serum (FCS;
GE Healthcare, Colbe, Germany), L-glutamine, HEPES,
and antibiotics. Adhering cells were grown to subcon-
fluence and split subsequently by trypsinization. Cells
were used for experiments from passage 3 until passage
9 at 70 to 90% confluence. To generate hypoxic condi-
tions, cells were cultured for 48 h at 1% O2. Control plates
were incubated with 20% O2 (normoxia).
For flow cytometric analysis, cells were incubated for
30 min with anti-CD55-APC (clone IA10) or isotype con-
trol IgG2a-APC and analyzed on a FACSCalibur (all BD
Biosciences, San Jose, CA, USA). Results were analyzed
using FlowJo software (Tree Star Inc, Ashland, OR, USA).
For real-time polymerase chain reaction (PCR) analysis,
total RNA was isolated using the Qiagen RNA extraction
kit (Qiagen, Venlo, Netherlands). A total of 100 ng total
RNA was reverse transcribed using oligo(dT), random
hexamers, and M-MuLV reverse transcriptase from the
First Strand cDNA Synthesis kit (Thermo Fisher Scientific,
Waltham, MA, USA). Transcript levels of the hypoxia-
regulated genes vascular endothelial growth factor (VEGF),
leptin (LEP), and angiopoietin-like 4 (ANGPTL4) [17] were
analyzed by quantitative PCR with the StepOnePlus Real-
Time PCR system using Fast SYBR Green Master Mix
(Applied Biosystems, Carlsbad, CA, USA). The following





5′-CGGAAGTACTGGCCGTTGAG-3′; 18S rRNA 5′-
CGGCTACCACATCCAAGGAA-3′ and 5′-GCTGGA
ATTACCGCGGCT-3′. Gene transcription was normal-
ized to 18S rRNA (ΔCt). The relative expression ratios
were calculated using the 2-ΔΔCt method.
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Micromass organ cultures were constructed as described
elsewhere [4,5]. Briefly, FLS were released from the cul-
ture dish by trypsinization and resuspended in ice-cold
Matrigel matrix (BD Biosciences) at a density of 3 to 5 ×
106 cells/ml. Droplets of the cell suspension (25 μl) were
placed onto 12-well culture dishes, coated with poly-2-
hydroxyethyl methacrylate (poly-HEMA; Sigma-Aldrich,
Milwaukee, WI, USA) to prevent attachment of cells to
the culture dish. Gelation was allowed for 30 min at 37°C.
Thereafter, the FLS gel was overlaid with basal culture
medium (DMEM with 10% FCS). The floating three-
dimensional cultures were maintained for 6 weeks; the
medium was routinely replaced twice weekly. For immu-
nohistochemistry, all micromasses were fixed with 4%
paraformaldehyde in PBS and embedded in paraffin.
For stimulation experiments, FLS-containing micro-
masses were cultured in basal medium or in basal
medium containing 10 ng/ml tumor necrosis factor
(TNF) (R&D Systems, Minneapolis, MN, USA) for the
14- to 28-day experimental course.
Histology and immunohistochemistry
For (immuno)histochemical staining, paraffin sections were
deparaffinized, rehydrated, and subjected to antigen re-
trieval by immersing them in sodium citrate buffer, pH 6.0,
inside an 86°C-water bath. Endogenous peroxidase activity
was blocked with 1% H2O2. Slides were incubated for 1 h
with a primary anti-CD55 (clone 143–30; LifeSpan
BioSciences, Seattle, WA, USA) or anti-collagen III anti-
body (clone III-53; Acris Antibodies, Herford, Germany),
washed, incubated with a secondary biotinylated goat-
anti-mouse antibody (Vector Laboratories, Burlingame,
CA, USA), and developed using a horseradish peroxidase
detection kit (VECTASTAIN Elite ABC Kit and DAB sub-
strate; Vector Laboratories). Images were captured with
an Axioscope 2 light microscope (Zeiss, Jena, Germany)
and processed using CellF software (Olympus Soft
Imaging Solutions, Münster, Germany). Gomori’s silver
impregnation was performed as described previously [4,5].
For immunofluorescent staining, frozen slides were
thawed, fixed in acetone, washed in PBS, and blocked
with 10% normal human serum. Sections were incubated
with primary fluorescein isothiocyanate (FITC)-labeled
anti-CD55 antibody (clone IA10; BD Biosciences) over-
night at 4°C, washed, and analyzed by confocal micros-
copy. To visualize colocalization of CD55 with other
stromal/ECM markers, FITC-conjugated mouse anti-
CD55 was combined with rat anti-ER-TR7 (Abcam,
Uithoorn, Netherlands) or biotinylated rabbit anti-
collagen I (Abcam) or biotinylated rabbit anti-collagen
III (Abcam), or biotinylated mouse anti-CD90 (clone
5E10; Biolegend, Uithoorn, Netherlands). From every sec-
tion, we took three to six confocal microscope images.Localization of C3b was detected using FITC-conjugated
rabbit anti-human C3c (Dako, Heverlee, Belgium), which
recognizes deposited C3b in tissue. After washing in PBS,
tissue sections were stained with secondary fluorescent-
labeled antibodies. All sections were mounted with
Vectashield containing DAPI (Vector Laboratories). Pho-
tographs were taken with a TCS SP8 X confocal micro-
scope, using X Pro imaging software (both from Leica
Geosystems, Munich, Germany). Image processing was
done using Photoshop software (Adobe Systems, San Jose,
CA, USA).
In situ hybridization
In situ hybridization for CD55 was performed in paraffin
sections of synovial tissue using a 5′-fluorescein-labeled
19-mer locked nucleic acid (LNA) antisense oligonucleo-
tide containing LNAs (capital letters) and 2′-O-methyl-
RNAs (small letters): 5′-FAM-TauGccAccTggTacAucA-3′
(Ribotask ApS, Odense, Denmark). Sections were depar-
affinized, boiled in 10 mM citrate buffer (pH 6) for
10 min, and hybridized at 60°C for 30 min in 50% (v/v)
deionized formamide, 600 mM NaCl, 10 mM HEPES
buffer (pH 7.5), 1 mM EDTA, 5 x Denhardt’s reagent,
and 200 ug/ml denaturated herring sperm with 100 nM
of CD55 oligonucleotide. After hybridization, tissue sec-
tions were washed for 5 min each in 2 x, 0.5 x, and 0.2 x
standard saline citrate at 60°C. Hybridized oligonucleo-
tides were detected by incubation for 1 h with 1:2000
dilution of AP-labeled anti-5’-fluorescein Fab fragments
(Roche, Woerden, Netherlands) and visualization using
Alkaline Phosphatase Substrate kit III (Vector Laboratories)
and Nuclear Fast Red (Sigma-Aldrich) counterstaining.
Mice and generation of bone marrow chimeras
Fcgr2b−/− mice generated using C57BL/6 embryonic
stem cells were previously described by us [18]. The gen-
eration of Cd55−/− mice using C57BL/6 embryonic stem
cells will be described elsewhere. Cd55−/− mice were
crossed with Fcgr2b−/− mice in order to obtain Fcgr2b−/− x
Cd55−/− mice. All animal experiments were approved by
the Animal Experiment Committee of the Leiden Univer-
sity Medical Center.
Bone marrow chimeras were generated by lethal irradi-
ation of recipient mice with 8 Gy for 10 min, followed by
retro-orbital injection with 8 × 106 nucleated donor bone
marrow cells 6 h later. Injection of Fcgr2b−/− mice with
bone marrow cells from Fcgr2b−/− mice resulted in
Fcgr2b−/− x Cd55host+/+BM+/+ mice, injection of Fcgr2b−/−
mice with bone marrow cells from Fcgr2b−/− x Cd55−/−
mice resulted in Fcgr2b−/− x Cd55host+/+BM−/− mice, and
injection of Fcgr2b−/− x Cd55−/− mice with bone marrow
cells from Fcgr2b−/− mice resulted in Fcgr2b−/− x
Cd55host−/−BM+/+ mice. During the 4 weeks after bone
marrow transplantation, mice received drinking water
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stitution, a few drops of blood were collected from the
tail vein after 5 weeks and analyzed by flow cytometry
for CD55 expression on T, B, and myeloid cells. All cells
were confirmed to be of donor origin.
K/BxN serum transfer model and evaluation of arthritis
development
Serum was harvested from 5- to 6-week-old K/BxN
arthritic mice and stored at −80°C until usage. Arthritis
was induced in recipient animals by intraperitoneal in-
jection (12.5 μl serum/g body weight) on day 0 and day
2. Disease development was evaluated over 10 days using
an extended scoring protocol [19]. In short, arthritic toes
and knuckles were scored as 1, arthritic ankles or mid
paws were evaluated on a scale from 1 to 5; so, each limb
obtained a score between 0 and 15. Each mouse therefore
could reach a total score of 60. Ankle thickness of each
hind paw was measured using a caliper (Mitutoyo, Aurora,
IL, USA) and compared with ankle thickness of the same
hind paw at day 0.
Mice were sacrificed on day 10. Right hind paws were
dissected, fixed in 4% buffered formalin for 1 day, demi-
neralized with Osteosoft (Merck, Darmstadt, Germany)
for 21 days, and embedded in paraffin. Sagittal 5-μm tissue
sections were stained with hematoxylin and eosin to
evaluate level of inflammation and with toluidine blue to
evaluate loss of proteoglycans from cartilage matrix. The
severity of joint inflammation was determined in a blinded
manner by two independent observers using an arbitrary
score (0 to 3, where 0 = no cells; 1 =mild cellularity; 2 =
moderate cellularity; 3 =maximal cellularity). The cartil-
age destruction was measured as proteoglycan loss (%
destained of total cartilage) using Image J software [20].
Image processing was done using Photoshop.
Preparation of single-cell suspensions and flow cytometry
A few drops of blood were collected from the tail vein into
heparin. Erythrocytes were lysed with a buffer containing
155 mM NH4Cl, 10 mM KHCO3, and 1 mM EDTA, and
the remaining cells were washed in PBA. Synovial tissue
was isolated from the left knee by medial patellar ligament
incision. Single-cell suspensions were obtained by diges-
tion with Liberase TM (0.4 mg/ml; Roche) and DNAse I
(1 mg/ml; Roche) for 15 min, followed by mashing the
remaining tissue in RPMI/10% FCS through a 70-μm cell
strainer. After enzymatic treatment, cells were washed
with PBA and stained directly. Nonspecific binding of
antibodies was blocked by adding 10% normal mouse
serum and 2.5 μg/ml anti-CD16/32 (clone 2.4G2; BD
Biosciences) for 30 min at 4°C. Cells were stained with
fluorescent-labeled antibodies to CD3, CD4, CD8, Ly-6G,
CD11b, CD19 (all eBiosciences), and CD55 (BD Biosci-
ences) for 30 min at 4°C. Viable cells were gated byforward and side scatter pattern. Flow cytometric ana-
lysis was performed using a FACSCanto (BD Biosci-
ences) and the FlowJo software package.
Statistics
Differences between more than two groups of mice after
arthritis induction were evaluated with repeated mea-
sures analysis of variance (ANOVA) with Bonferonni
post hoc test. P values ≤0.05 were considered to be sta-
tistically significant.
Results
Abundant presence of CD55 is an in situ characteristic of
the intimal lining layer of the synovium
Immunofluorescence staining of RA synovial tissue re-
vealed the characteristic, marked presence of CD55 in the
intimal lining layer (Figure 1A). A strong staining was ob-
tained with a FITC-labeled CD55 antibody without further
signal amplification, closely matching results obtained with
immunohistochemistry (Figure 1B). In situ hybridization
with a CD55-specific antisense LNA oligomer generated a
corresponding pattern, confirming that lining cells, pre-
viously identified as FLS [7], are the primary source of
CD55 gene expression in synovial tissue (Figure 1C).
The hybridization signal of CD55 in the synovial sublin-
ing was weaker, yet detectable, which fits its wide cellu-
lar distribution, including most immune cells [21].
FLS, obtained from synovial tissue by enzymatic diges-
tion, are widely used to study pathogenic mechanisms in
RA. Notably, cultured FLS expressed rather moderate
levels of CD55 mRNA, corresponding with quantities in
peripheral blood mononuclear cells (Figure S1A in
Additional file 1). We have recently tested the ability of
proinflammatory cytokines and pathogen-associated mo-
lecular patterns to upregulate CD55 on cultured FLS and
found that only double-stranded RNAs moderately en-
hanced its expression [14], not explaining the prominent
presence in the intimal lining layer. CD55 is a hypoxia-
induced gene in epithelial cells [22], and we reasoned that
hypoxic conditions in the synovium [23] might contribute
to its high intimal expression. However, culture of FLS at
hypoxic conditions (1% O2) did not cause upregulation
of CD55 mRNA or protein in FLS (Figure S1B/C in
Additional file 1). We concluded that abundant expres-
sion of CD55 is a characteristic of the synovial intima
that is not preserved in primary FLS cultures.
Expression of CD55 in the intimal lining layer coincides
with collagenous fibers
Microscopy of synovial tissue revealed a distinct fibrillar
staining pattern of CD55 (Figure 1A/B) indicating a pos-
sible extracellular distribution. To test this hypothesis,
we stained paraffin sections of synovial tissue first with a
CD55 or collagen III antibody and subsequently with
Figure 1 CD55 is expressed in the intimal lining layer of rheumatoid arthritis (RA) synovial tissue. (A) Sections of RA synovial tissue were
stained with a fluorescein isothiocyanate (FITC)-labeled CD55 antibody (clone IA10) and analyzed by confocal microscopy. Note the fibrillar
appearance of the fluorescent signal; magnification 20 x. (B) RA synovial tissue sections were stained with a CD55 antibody (clone 143–30) and
visualized by immunohistochemistry and light microscopy; magnification 20 x. (C) In situ hybridization, using an antisense locked nucleic acid
(LNA) oligomer, detects CD55 transcripts primarily in the synovial lining. Representative images are shown; magnification 10 x.
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lagenous fibers [24,25]. The silver impregnation revealed
a meshwork of fibers, a pattern closely matching the dis-
tribution of collagen III at both the intimal lining layer
and the synovial sublining area (Figure 2A/B). At the in-
timal lining layer, CD55 staining coincided with these fi-
bers (Figure 2C/D), suggesting localization of CD55 with
collagenous fibers, specifically at the intima.
Three-dimensional micromasses, grown from FLS,
mimic phenotypic characteristics of the normal and the
hyperplastic intimal lining layer [5]. When staining
three-dimensional micromasses, we detected a CD55
signal after about 3 to 4 weeks of culture that was not
visible at earlier time points (Figure 3A/E). As in syn-
ovial tissue, CD55 staining appeared as a fibrillar pat-
tern within and at the basis of the intimal lining layer.
Gomori silver staining of micromasses confirmed the de-
velopment of reticular fibers within time (Figure 3B/F).
Addition of TNF caused hyperplasia of the lining [5],
coinciding with an intensified CD55 signal (Figure 3C/G)
and more refined collagenous fibers visualized by Gomori
silver staining and collagen III immunohistochemistry
(Figure 3D/H and Figure S2 in Additional file 1). Thus,
three-dimensional FLS micromasses develop over time
the characteristic fibrillar CD55 expression pattern
found in the intimal lining layer and, in parallel, a col-
lagenous meshwork.
Cellular CD55 is attached to the plasma membrane by
a GPI anchor, accessible to cleavage by phospholipase C
[26]. ECM-attached CD55, in contrast, is not sensitive
to phospholipase C cleavage [27,28]. Tissue sections,
treated with phospholipase C prior to immunofluores-
cent staining, retained the signal for CD55, but not for
CD90 (Thy-1), which also is a GPI-anchored molecule
(Figure S3 in Additional file 1). Therefore, we concluded
that the majority of CD55 in the synovial tissue is de-
posited extracellularly.Molecular composition of CD55+ collagenous fibers
Silver impregnation techniques, like Gomori’s method,
are widely used to detect reticular fibers. However, they
have no biochemical definition and cannot be used as
staining techniques for reticulin or different types of col-
lagen [29]. We therefore performed immunofluorescent
double staining of CD55 together with collagen I and III,
CD90, and ER-TR7 on RA synovial tissue sections. We de-
tected a clear colocalization of CD55 with collagen I and
collagen III in the intimal lining layer, but not the vascula-
ture, localized in the synovial sublining (Figure 4A/B and
Figure S4A/C in Additional file 1). The latter was con-
firmed by costaining CD55 with CD90, a marker expressed
by endothelial cells (Figure 4C).
Collagens are constituents of collagen fibers; however,
collagen III also builds the core of reticular fibers [24,25].
ER-TR7 is an antigen of unknown origin expressed by
fibroblast-like reticular cells [30] and used commonly to
visualize the reticular network in lymph nodes [31,32]. We
found an ER-TR7+ network in the synovial sublining that
did not overlap with the CD55+ collagenous fibers in the
lining (Figure 4D and Figure S4B in Additional file 1).
Thus, deposition of CD55 is a distinct characteristic of
collagenous fibers in the intimal lining layer, but not of
the ER-TR7+ network in the sublining.
The unique localization of CD55 at the edge of the
synovial tissue, conjugated to collagenous fibers, implied
a possible role of CD55 in protecting the synovial tissue
from attack by complement. Confirming previous re-
ports [33,34], we detected C3b in the intimal lining layer
with a distribution similar to CD55 (Figure S5 in
Additional file 1).
CD55 cooperates with FcγRIIB (CD32) in protecting
against immune complex-mediated arthritis
To address the possibility that CD55 protects the synovial
tissue from complement-mediated immune activation
Figure 2 Expression pattern of CD55 and collagen III coincides with collagenous structures in rheumatoid arthritis (RA) synovial tissue.
Sections of RA synovial tissue first were stained with (A) anti-collagen antibody or (C) anti-CD55 antibody and then processed to (B/D) Gomori
silver impregnation. Red arrowheads indicate localization of CD55 to collagenous fibers. Shown are representative stainings derived by light
microscopy; magnification 20 x.
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arthritis. The K/BxN model is driven by immune com-
plexes and depends on complement, Fc receptors, and in-
nate immune cells, mainly neutrophils [35-37]. In analogy
with the situation seen in RA synovial tissue, we observed
intensive collagen III staining in the intimal lining layer in
arthritic mice (Figure 5A).
Notably, we previously reported a slight protection of
mice lacking CD55 in the K/BxN model, which mirrored
a similar phenotype in mice lacking the CD55 interact-
ing partner CD97 [13]. In the current study, we used less
potent serum to have a higher threshold for disease de-
velopment. In this setting, mice lacking CD55, like wild-type mice, did not develop arthritis (Figure 5B). In con-
trast, mice lacking FcγRIIB (Fcgr2b−/−) were susceptible,
which fits with the crucial role of this inhibitory receptor
in the control of immune complex-mediated inflammation
[18]. When we crossed Cd55−/− mice with Fcgr2b−/− mice,
compound animals developed significantly more severe
disease than mice that only lack FcyRIIB (Figure 5B). Cor-
responding herewith, Fcgr2b−/− x Cd55−/− mice showed a
trend toward enhanced cartilage destruction and immune
cell infiltration (Figure 5C) with more Gr1+CD11b+ granu-
locytes present locally in the synovial tissue (Figure 5D).
Thus, combined absence of FcγRIIB receptor and CD55
deteriorates K/BxN serum-induced arthritis.
Figure 3 Expression pattern of CD55 coincides with collagenous structures in three-dimensional fibroblast-like synoviocytes (FLS)
micromasses. (A, B, E, F) Sections of three-dimensional FLS micromasses were stained with anti-CD55 antibody at day 14 (A) and day 28
(E), and then processed to Gomori silver impregnation (B and F, respectively). (C, D, G, H) Sections of three-dimensional FLS micromasses, which
were cultured with 10 ng/ml tumor necrosis factor (TNF), were stained with anti-CD55 antibody at day 14 (C) and day 28 (G), and then processed
to Gomori silver impregnation (D and H, respectively). Red arrowheads indicate a similar distribution of CD55 and collagenous fibers. Shown are
representative stainings derived by light microscopy; magnification 40 x.
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stromal cells [8,18]. To explore the role of stromal CD55
in arthritis development, as an extrapolation to human
CD55, abundantly expressed by FLS, we generated bone
marrow chimeric mice expressing CD55 on either im-
mune or non-immune cells. We found that Fcgr2b−/− x
Cd55host+/+BM−/− and Fcgr2b−/− x Cd55host−/−BM+/+ mice
were equally susceptible to K/BxN serum transfer arth-
ritis compared to Fcgr2b−/− x Cd55host+/+BM+/+ mice
(Figure 5E) with a tendency toward slightly higher dis-
ease scores and granulocyte infiltration in synovial tissue
(Figure 5E/F). We concluded that CD55 on bothimmune and stromal cells is contributing to protection
against immune complex-mediated arthritis in suscep-
tible mice.
Discussion
We here report that CD55, produced by FLS, is depos-
ited in large amounts at a collagenous fiber network
within and at the basis of the intimal lining layer. Fiber
networks building the ECM provide structural support
for organs and tissues, for cell layers in the form of base-
ment membranes and for individual cells as substrates for
migration. Moreover, they are essential for the binding,
Figure 4 CD55 colocalizes with collagen I and collagen III, but not with ER-TR7 or CD90 in rheumatoid arthritis (RA) synovial tissue.
Sections of RA synovial tissue were costained for CD55 (green) and (A) collagen I, (B) collagen III (C) CD90, or (D) ER-TR7 (all red, overlay yellow)
and analyzed by confocal microscopy. Shown are representative stainings, magnification 63 x.
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tory signals, chemoattractants, and soluble antigens that
govern the differentiation, proliferation, survival, polarity,
and migration of immune cells [38]. The synovial tissue
comprises various ECM structures [39], which are synthe-
sized by FLS. More recent studies with three-dimensional
micromasses unveiled that FLS are capable of autono-
mously establishing a complex basement membrane-like
structure that enables the intimal lining layer-synovial
sublining architecture as well as fibrilliar meshworks in
lining and sublining [5].Deposition of CD55 on structures of the ECM was
first reported by Medof and coworkers, who noted a
prominent fibrillar staining in fibrous sheaths surround-
ing myocardial muscle bundles, in interstitium under-
lying the endocardium, and in connective tissue adjacent
to the synovium [40]. Later studies confirmed and ex-
tended these findings by describing CD55 attached to
subendothelial collagenous fibers underneath the vascu-
lature [27] and various epithelia [41], as well as to elastic
fibers surrounding nerve plexuses of the enteric nervous
system [28]. Notable is the expression of CD55 in the
Figure 5 CD55 either on immune or stromal cells protects from K/BxN serum transfer-induced arthritis in the absence of FcγRIIB
(CD32). Mice were injected at day 0 with 12.5 μl/g K/BxN serum and followed for disease development. At day 10, animals were sacrificed for
further analysis. (A) Collagen III staining in representative knee joint sections of non-diseased and arthritic Fcgr2b−/− mice. Magnification 20 x.
(B) Development of arthritis evaluated by measuring clinical scores and ankle thickness. Depicted are mean ± standard error of the mean (SEM)
of five animals per group. ***, P <0.001; **, P <0.01; *, P <0.05 (C) Histological evaluation of knee joints for proteoglycan loss (toluidine blue; above)
and cell infiltration (hematoxylin and eosin; below). Photographs are representative of mice with no or highest disease activity in the
experiment, respectively. Joint structures are labeled as F, femur; M, meniscus; S, synovium; T, tibia. Magnification 5 x. (D) Flow cytometry plots of
isolated synovial tissue cells stained for CD11b+Gr1+ granulocytes, representative of mice with no or highest disease activity in the experiment,
respectively. (E) Development of arthritis evaluated by measuring clinical scores and ankle thickness in bone marrow chimeric mice that lacked
CD55 on stromal cells (Fcgr2b−/− x Cd55host−/−BM+/+, depicted as a dark green line), on immune cells (Fcgr2b−/− x Cd55host+/+BM−/−, depicted as a
light green line), or on none of the two compartments (Fcgr2b−/− x Cd55host+/+BM+/+, depicted as a red line). Depicted are mean ± SEM values of
five animals per group. (F) Flow cytometry plots of isolated synovial tissue cells stained for CD11b+Gr1+ granulocytes, representative of mice with
no or highest disease activity in the experiment, respectively. Quantifications provided to the right in (C), (D), and (F) show individual mice (dots)
with a horizontal line indicating the mean per group (n = 5).
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scribed deposition of large amounts of CD55 in stroma
surrounding infiltrating (adeno)carcinoma of the breast,
colon, kidney, and lung, while normal tissue stroma
showed only small, localized deposits [41]. In line here-
with, CD55 overexpression has been a target for intes-
tinal tumor imaging, conferring with a poor prognosis in
colorectal cancer patients [42]. Together, these findings
suggest that abnormal expression of CD55 in the human
body, as seen in tumors and the arthritic intimal lining
layer, coincides with its deposition on ECM structures.
The collagenous ECM system comprises different mesh-
works [24,25]. By studying RA synovial tissue and three-
dimensional RA FLS micromasses, we here show that
CD55 in synovial tissue is deposited on collagen type I+/III+
fibers, which are restricted to and established along with
the intimal lining, where FLS are compacted. Despite
visualization of these fibers by silver impregnation, they did
not stain for ER-TR7, a marker widely used to identify re-
ticular networks [24,25]. Notably, ER-TR7 antibody gener-
ated a widespread staining pattern, almost inverse to the
CD55+ network, in the synovial sublining. Whether this
ER-TR7 network, in line with its role in secondary lymph-
oid organs [31,32], facilitates ectopic lymphoid neogenesis
in synovial tissue remains to be investigated. Our data
imply the existence of different fiber meshworks in the syn-
ovial tissue, which may serve distinct functions.
The mechanism of CD55 deposition on synovial ECM
remains to be established. Of note, development of the
CD55+ collagenous network was enhanced in micro-
masses grown with TNF, demonstrating that FLS respond
to proinflammatory stimuli by expanding the intimal lin-
ing layer including its ECM components. This finding
matches observations that formation of the reticular net-
work by fibroblast reticular cells in lymph nodes requires
TNF receptor engagement [31], suggesting an essential
role of TNF in the development of different collagenous
meshworks. Anti-TNF therapy may affect this system,
providing an additional mechanism of its action [43].
Previous studies by Hindmarsh and Marks showed that
complement activation occurs on ECM and can be con-
trolled by matrix-bound CD55 [27,44]. The need for an
effective control of complement in the synovium is evi-
dent from studies showing consumption of complement
components and generation of complement activation
products in the synovial fluid of RA patients [45-47].
Moreover, C3 is deposited on the surface of cartilage and
synovium in RA [33,34] and in experimental models of
arthritis [48,49]. Circulating C3 is necessary and sufficient
for antibody-driven K/BxN serum transfer arthritis [36].
Nevertheless, in different settings of this model, studied
here and previously by our group [13], deletion of CD55
did not aggravate arthritis activity. In contrast, lack of
CD55 further enhanced disease activity in Fcgr2b−/− mice,which are highly susceptible to the K/BxN serum trans-
fer model [18]. The adverse effect of CD55 deficiency in
compound animals was not seen in bone marrow
chimeric mice that expressed CD55 either on immune
or non-immune cells, indicating that CD55 on both cel-
lular compartments contributes to the control of com-
plement activation.
Immune complex-mediated inflammation is mediated
by a molecular partnership between Fc-gamma receptors
(FcγRs), complement receptors, and additional modula-
tors, such as C-type lectins [50]. Complement activation
generates C5a, which by binding to its receptor (C5aR;
CD88) lowers the threshold for FcγR activation through
changing the ratio of expression of activating (FcγRI and
FcγRIII) and inhibitory (FcγRIIB) receptors [51]. Con-
versely, immune complexes binding to FcγR enhance the
synthesis of C5 and, consequently, promote the gener-
ation of C5a. This positive-feedback loop [52] essentially
contributes to the pathogenesis of inflammatory disor-
ders; however, the factors that tip the balance toward
disease have remained elusive, and little is known re-
garding the mechanisms that circumvent C5a-induced
excessive tissue immune activation and damage [52].
Our study suggests that CD55, which accelerates the
decay of C3 convertases [8], provides a safety mechan-
ism that is of critical importance once the activating-
inhibitory FcγR ratio turns toward more activation.Conclusions
Our findings suggest that the abundant presence of CD55
in the intimal lining layer of the synovial tissue is due to
deposition on a local meshwork of collagenous fibers that
compacts the cellular compartment. Moreover, this study
helps clarify the roles of CD55 in the pathogenesis of
arthritis by demonstrating involvement in the protection
against immune complex-mediated K/BxN serum transfer
arthritis in susceptible mice lacking the inhibitory FcγRIIB.Additional file
Additional file 1: Figure S1. Cultured FLS express average levels of
CD55. Figure S2. Expression pattern of collagen III in three-dimensional
FLS micromasses coincides with collagenous structures visualized by
Gomori silver staining. Figure S3. CD55, deposited in the extracellular
matrix of the synovial lining, is resistant to phospholipase C treatment.
Figure S4. Collagen I in synovial tissue colocalizes with CD55, ER-TR7,
von Willebrand factor. Figure S5. Collagen I in synovial tissue colocalizes
with complement component C3b.Abbreviations
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FCS: fetal calf serum; FcγRs: Fc-gamma receptors; FITC: fluorescein
isothiocyanate; FLS: fibroblast-like synoviocytes; GPCR: G protein-coupled
receptor; GPI: glycosylphosphatidylinositol; kDa: kiloDalton; LNA: locked
nucleic acid; PBS: phosphate-buffered saline; PCR: polymerase chain reaction;
RA: rheumatoid arthritis; RNA: ribonucleic acid; TNF: tumor necrosis factor.
Karpus et al. Arthritis Research & Therapy  (2015) 17:6 Page 11 of 12Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
ONK designed the study, analyzed human tissues, carried out mouse
experiments, performed statistical analyses, and drafted the manuscript.
HPK participated in the design and coordination of the study and helped
to draft the manuscript. BN carried out the three-dimensional micromass
experiments. ASYE generated K/BxN serum and helped with the mouse
experiments. JvdK generated and bred mouse strains. VR helped with the
analysis of complement expression. RA generated bone marrow chimeras.
JSS secured funding and helped coordinate the study. MB provided Cd55−/−
mice. PPT participated in the design and coordination of the study and
secured funding. JSV participated in the design and coordination of the
study, provided Fcgr2b−/− mice, and helped with the mouse experiments.
JH designed and coordinated the study, secured funding, helped with the
mouse experiments, and drafted the manuscript. All authors read, revised,
and approved the final manuscript.
Acknowledgements
We thank our colleagues from the Division of Clinical Immunology and
Rheumatology at the Academic Medical Center of Amsterdam and the
Department of Orthopedics at the Medical University of Vienna for providing
synovial tissue samples, the Cellular Imaging facility at the Academic Medical
Center of Amsterdam (LCAM-AMC) for supporting the microscopy
experiments, Dr. Kees Fluiter and Karolina von Dalwigk for experimental help,
Dr. Talat Malik and the transgenic facility of the Leiden University Medical
Center for generating Cd55−/− mice, and Dr. Luigi Varesio, Dr. Leendert
Trouw, and Prof. Jörg Köhl for valuable suggestions.
Funding
This work was supported by grants from the Dutch Arthritis Association (NR
07-01-404) to JH, from the European Union’s Innovative Medicines Initiative,
acronym BTCure (115142) to JSS and PPT, and from the European Union,
acronym IMDEMI, (MRTN-CT-2004-005632) to MB and JSV.
Author details
1Departments of Experimental Immunology, Internal Medicine, and Genetics,
Room K0-140, Academic Medical Center, University of Amsterdam,
Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands. 2Department of
Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna
General Hospital, Währinger Gürtel 18-20, A-1090 Vienna, Austria.
3Departments of Human Genetics and Immunohematology and Blood
Transfusion, Leiden University Medical Center, Albinusdreef 2, 2333 ZA
Leiden, The Netherlands. 4Centre for Complement & Inflammation Research,
Department of Medicine, Imperial College London, South Kensington
Campus, London SW7 2AZ, UK. 5GlaxoSmithKline Pharmaceuticals Research
and Development, Gunnels Wood Road, Stevenage SG1 2NY, UK.
Received: 17 April 2014 Accepted: 6 January 2015
References
1. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature.
2003;423:356–61.
2. Noss EH, Brenner MB. The role and therapeutic implications of fibroblast-like
synoviocytes in inflammation and cartilage erosion in rheumatoid arthritis.
Immunol Rev. 2008;223:252–70.
3. Bartok B, Firestein GS. Fibroblast-like synoviocytes: key effector cells in
rheumatoid arthritis. Immunol Rev. 2010;233:233–55.
4. Kiener HP, Lee DM, Agarwal SK, Brenner MB. Cadherin-11 induces rheumatoid
arthritis fibroblast-like synoviocytes to form lining layers in vitro. Am J Pathol.
2006;168:1486–99.
5. Kiener HP, Watts GF, Cui Y, Wright J, Thornhill TS, Skold M, et al. Synovial
fibroblasts self-direct multicellular lining architecture and synthetic function
in three-dimensional organ culture. Arthritis Rheum. 2010;62:742–52.
6. Stevens CR, Mapp PI, Revell PA. A monoclonal antibody (Mab 67) marks
type B synoviocytes. Rheumatol Int. 1990;10:103–6.
7. Hamann J, Wishaupt JO, van Lier RA, Smeets TJ, Breedveld FC, Tak PP.
Expression of the activation antigen CD97 and its ligand CD55 in
rheumatoid synovial tissue. Arthritis Rheum. 1999;42:650–8.8. Lublin DM, Atkinson JP. Decay-accelerating factor: biochemistry, molecular
biology, and function. Annu Rev Immunol. 1989;7:35–58.
9. Song WC. Complement regulatory proteins and autoimmunity.
Autoimmunity. 2006;39:403–10.
10. Hamann J, Vogel B, van Schijndel GM, van Lier RA. The seven-span
transmembrane receptor CD97 has a cellular ligand (CD55, DAF). J Exp Med.
1996;184:1185–9.
11. Langenhan T, Aust G, Hamann J. Sticky signaling-adhesion class G
protein-coupled receptors take the stage. Sci Signal. 2013; 6:re3.
12. Kop EN, Kwakkenbos MJ, Teske GJ, Kraan MC, Smeets TJ, Stacey M, et al.
Identification of the epidermal growth factor-TM7 receptor EMR2 and its
ligand dermatan sulfate in rheumatoid synovial tissue. Arthritis Rheum.
2005;52:442–50.
13. Hoek RM, de Launay D, Kop EN, Yilmaz-Elis AS, Lin F, Reedquist KA, et al.
Deletion of either CD55 or CD97 ameliorates arthritis in mouse models.
Arthritis Rheum. 2010;62:1036–42.
14. Karpus ON, Heutinck KM, Wijnker PJ, Tak PP, Hamann J. Triggering of the
dsRNA sensors TLR3, MDA5, and RIG-I induces CD55 expression in synovial
fibroblasts. PLoS One. 2012;7:e35606.
15. Gerlag DM, Tak PP. How to perform and analyse synovial biopsies. Best
Pract Res Clin Rheumatol. 2009;23:221–32.
16. The 2010 ACR-EULAR classification criteria for rheumatoid arthritis.
http://www.rheumatology.org
17. Larsen H, Muz B, Khong TL, Feldmann M, Paleolog EM. Differential effects of
Th1 versus Th2 cytokines in combination with hypoxia on HIFs and
angiogenesis in RA. Arthritis Res Ther. 2012;14:R180.
18. Boross P, Arandhara VL, Martin-Ramirez J, Santiago-Raber ML, Carlucci F,
Flierman R, et al. The inhibiting Fc receptor for IgG, FcgammaRIIB, is a
modifier of autoimmune susceptibility. J Immunol. 2011;187:1304–13.
19. Boross P, van Lent PL, Martin-Ramirez J, van der Kaa J, Mulder MH,
Claassens JW, et al. Destructive arthritis in the absence of both FcgammaRI
and FcgammaRIII. J Immunol. 2008;180:5083–91.
20. Image processing and analysis in Java. http://rsb.info.nih.gov/ij/
21. Terstappen LW, Nguyen M, Lazarus HM, Medof ME. Expression of the DAF
(CD55) and CD59 antigens during normal hematopoietic cell differentiation.
J Leukoc Biol. 1992;52:652–60.
22. Louis NA, Hamilton KE, Kong T, Colgan SP. HIF-dependent induction of
apical CD55 coordinates epithelial clearance of neutrophils. FASEB J.
2005;19:950–9.
23. Ng CT, Biniecka M, Kennedy A, McCormick J, Fitzgerald O, Bresnihan B, et al.
Synovial tissue hypoxia and inflammation in vivo. Ann Rheum Dis.
2010;69:1389–95.
24. Montes GS. Structural biology of the fibres of the collagenous and elastic
systems. Cell Biol Int. 1996;20:15–27.
25. Ushiki T. Collagen fibers, reticular fibers and elastic fibers: a comprehensive
understanding from a morphological viewpoint. Arch Histol Cytol. 2002;65:109–26.
26. Davitz MA, Low MG, Nussenzweig V. Release of decay-accelerating factor
(DAF) from the cell membrane by phosphatidylinositol-specific phospholipase
C (PIPLC): selective modification of a complement regulatory protein. J Exp
Med. 1986;163:1150–61.
27. Hindmarsh EJ, Marks RM. Decay-accelerating factor is a component of
subendothelial extracellular matrix in vitro, and is augmented by activation
of endothelial protein kinase C. Eur J Immunol. 1998;28:1052–62.
28. Gelderman KA, Zijlmans HJ, Vonk MJ, Gorter A. CD55 expression patterns
on intestinal neuronal tissue are divergent from the brain. Gut.
2004;53:507–13.
29. Puchtler H, Waldrop FW. Silver impregnation methods for reticulum fibers
and reticulin: a re-investigation of their origins and specificity. Histochemistry.
1978;57:177–87.
30. Van Vliet E, Melis M, Foidart JM, Van Ewijk W. Reticular fibroblasts in
peripheral lymphoid organs identified by a monoclonal antibody.
J Histochem Cytochem. 1986;34:883–90.
31. Katakai T, Hara T, Sugai M, Gonda H, Shimizu A. Lymph node fibroblastic
reticular cells construct the stromal reticulum via contact with lymphocytes.
J Exp Med. 2004;200:783–95.
32. Malhotra D, Fletcher AL, Astarita J, Lukacs-Kornek V, Tayalia P, Gonzalez SF,
et al. Transcriptional profiling of stroma from inflamed and resting lymph
nodes defines immunological hallmarks. Nat Immunol. 2012;13:499–510.
33. Vetto AA, Mannik M, Zatarain-Rios E, Wener MH. Immune deposits in articular
cartilage of patients with rheumatoid arthritis have a granular pattern not seen
in osteoarthritis. Rheumatol Int. 1990;10:13–9.
Karpus et al. Arthritis Research & Therapy  (2015) 17:6 Page 12 of 1234. Konttinen YT, Ceponis A, Meri S, Vuorikoski A, Kortekangas P, Sorsa T, et al.
Complement in acute and chronic arthritides: assessment of C3c, C9, and
protectin (CD59) in synovial membrane. Ann Rheum Dis. 1996;55:888–94.
35. Ji H, Ohmura K, Mahmood U, Lee DM, Hofhuis FM, Boackle SA, et al.
Arthritis critically dependent on innate immune system players. Immunity.
2002;16:157–68.
36. Monach PA, Verschoor A, Jacobs JP, Carroll MC, Wagers AJ, Benoist C, et al.
Circulating C3 is necessary and sufficient for induction of autoantibody-
mediated arthritis in a mouse model. Arthritis Rheum. 2007;56:2968–74.
37. Sadik CD, Kim ND, Iwakura Y, Luster AD. Neutrophils orchestrate their own
recruitment in murine arthritis through C5aR and FcgammaR signaling.
Proc Natl Acad Sci U S A. 2012;109:E3177–85.
38. Hynes RO. The extracellular matrix: not just pretty fibrils. Science.
2009;326:1216–9.
39. Scott DL, Salmon M, Walton KW. Reticulin and its related structural
connective tissue proteins in the rheumatoid synovium. Histopathology.
1984;8:469–79.
40. Medof ME, Walter EI, Rutgers JL, Knowles DM, Nussenzweig V. Identification
of the complement decay-accelerating factor (DAF) on epithelium and
glandular cells and in body fluids. J Exp Med. 1987;165:848–64.
41. Niehans GA, Cherwitz DL, Staley NA, Knapp DJ, Dalmasso AP. Human
carcinomas variably express the complement inhibitory proteins CD46
(membrane cofactor protein), CD55 (decay-accelerating factor), and CD59
(protectin). Am J Pathol. 1996;149:129–42.
42. Spendlove I, Li L, Carmichael J, Durrant LG. Decay accelerating factor
(CD55): a target for cancer vaccines? Cancer Res. 1999;59:2282–6.
43. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor
antagonist mechanisms of action: a comprehensive review. Pharmacol Ther.
2008;117:244–79.
44. Hindmarsh EJ, Marks RM. Complement activation occurs on subendothelial
extracellular matrix in vitro and is initiated by retraction or removal of
overlying endothelial cells. J Immunol. 1998;160:6128–36.
45. Mollnes TE, Lea T, Mellbye OJ, Pahle J, Grand O, Harboe M. Complement
activation in rheumatoid arthritis evaluated by C3dg and the terminal
complement complex. Arthritis Rheum. 1986;29:715–21.
46. Swaak AJ, van Rooyen A, Planten O, Han H, Hattink O, Hack E. An analysis of
the levels of complement components in the synovial fluid in rheumatic
diseases. Clin Rheumatol. 1987;6:350–7.
47. Olmez U, Garred P, Mollnes TE, Harboe M, Berntzen HB, Munthe E. C3
activation products, C3 containing immune complexes, the terminal
complement complex and native C9 in patients with rheumatoid arthritis.
Scand J Rheumatol. 1991;20:183–9.
48. Stuart JM, Dixon FJ. Serum transfer of collagen-induced arthritis in mice.
J Exp Med. 1983;158:378–92.
49. Matsumoto I, Maccioni M, Lee DM, Maurice M, Simmons B, Brenner M, et al.
How antibodies to a ubiquitous cytoplasmic enzyme may provoke
joint-specific autoimmune disease. Nat Immunol. 2002;3:360–5.
50. Karsten CM, Pandey MK, Figge J, Kilchenstein R, Taylor PR, Rosas M, et al.
Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and
association of FcgammaRIIB and dectin-1. Nat Med. 2012;18:1401–6.
51. Godau J, Heller T, Hawlisch H, Trappe M, Howells E, Best J, et al. C5a initiates
the inflammatory cascade in immune complex peritonitis. J Immunol.
2004;173:3437–45.
52. Ricklin D, Reis ES, Lambris JD. A sweet spot to control complement-induced
inflammation. Nat Med. 2012;18:1340–1.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
